ODI Pharma AB (ODI.ST) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-2478.3%

-SEK 31.63

vs SEK 1.33 price

Levered DCF

-SEK 29.24

After debt service

Piotroski score

6 / 9

Average

Altman Z-score

13.25

Safe zone

Rating

B-

Overall 3 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	21.82×	-6.81×	-190.35×	-11.78×	-11.49×	-16.54×	-15.55×	-40.67×
P/B	18.52×	49.19×	54.1×	31.35×	8.87×	4.02×	3.89×	36.74×
P/S	1.34×	12.88×	4.86×	578.43×	262.63×	0×	0×	0×
EV / EBITDA	15.65×	-7.51×	220.66×	-10.76×	-10.39×	-12.83×	-11.7×	-43.17×
Gross margin	31.2%	26.8%	20.7%	-4616.3%	-2310.4%	0.0%	0.0%	0.0%
Operating margin	7.6%	-168.3%	-8.6%	-4885.2%	-2310.4%	0.0%	0.0%	0.0%
Net margin	6.0%	-189.0%	-2.5%	-4948.6%	-2313.2%	0.0%	0.0%	0.0%
Current ratio	1.81×	1.16×	1.2×	1.46×	8.49×	29×	26.53×	10.47×
Debt / equity	0×	0×	0×	0×	0×	0×	0×	0×
Interest coverage	4.15×	-7.07×	-2.25×	-63.28×	-251.38×	-269.48×	-604.83×	-387.93×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	83.7%	-722.1%	-28.4%	-268.2%	-78.2%	-24.4%	-24.7%	-89.8%
Return on invested capital	105.4%	-643.0%	-96.1%	-264.8%	-78.1%	-24.1%	-23.5%	-85.6%
Return on assets	37.5%	-102.1%	-4.6%	-84.3%	-69.0%	-23.6%	-23.8%	-81.3%
Free cash flow yield	10.4%	-13.4%	-3.5%	-6.3%	-9.0%	-9.3%	-6.1%	-2.3%
Earnings yield	4.5%	-14.7%	-0.5%	-8.6%	-8.8%	-6.1%	-6.4%	-2.4%
Enterprise value	SEK 40.6M	SEK 38.6M	SEK 105.6M	SEK 74.2M	SEK 74.8M	SEK 50.8M	SEK 57.6M	SEK 144.1M
Net debt / EBITDA	-1.31×	0.29×	-5.52×	0.94×	1.02×	3.69×	4.17×	1.32×
Cash conversion cycle (days)	-7	129	54	2,296	1,649	4,577	-8,904	-7,699